The nasal route for vaccination offers both mucosal and systemic immunity for the prophylaxis of respiratory diseases. In order to induce maximal protective mucosal immunity, mucosal adjuvant is essential. Current studies are searching vaccinal antigens that are derived from the outer membrane protein (OMP) of Neisseria meningitidis. This study investigated the immunogenicity of intranasally administered class 5C protein of Neisseria meningitidis B employing purified LPS of the immunotypes (L3, 7, 9 or L8), cholera toxin and whole cells of Bordetella pertussis as mucosal adjuvants for the development of new meningococcal vaccine. In conclusion, the nasal delivery of class 5C with mucosal adjuvants has considerable potential in the development of a mucosal vaccine against serogroup B meningococci in a prime boost immunization in the presence of the adjuvants used. A monoclonal antibody against class 5 C protein using popliteal lymph nodes was obtained.